Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
0.4934
+0.0342 (7.45%)
Jul 28, 2026, 2:38 PM EDT - Market open
Heron Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 150.71 | 154.9 | 144.29 | 127.04 | 107.67 | 86.35 | |
Revenue Growth | 1.48% | 7.36% | 13.57% | 17.99% | 24.70% | -2.59% |
Cost of Revenue | 43.53 | 41.35 | 38.65 | 65.11 | 54.87 | 46.02 |
Gross Profit | 107.18 | 113.56 | 105.64 | 61.94 | 52.8 | 40.33 |
Selling, General & Admin | 105.11 | 103.67 | 100.48 | 133.42 | 144.75 | 127.33 |
Research & Development | 12.54 | 12.43 | 16.68 | 39.13 | 82.7 | 130.82 |
Total Operating Expenses | 117.64 | 116.1 | 117.17 | 172.55 | 227.46 | 258.15 |
Operating Income | -10.46 | -2.54 | -11.53 | -110.62 | -174.66 | -217.83 |
Interest Income | - | 1.95 | 3.55 | 3.36 | 1.64 | 0.43 |
Interest Expense | - | -9.61 | -6.03 | -3.87 | -2.47 | -2.41 |
Other Non-Operating Income (Expense) | -17.49 | -10 | 0.43 | 0.56 | -6.53 | -0.88 |
Total Non-Operating Income (Expense) | -17.49 | -17.66 | -2.05 | 0.06 | -7.37 | -2.86 |
Pretax Income | -10.46 | -20.2 | -13.58 | -110.56 | -182.02 | -220.68 |
Net Income | -10.46 | -20.2 | -13.58 | -110.56 | -182.02 | -220.68 |
Net Income to Common | -10.49 | -20.2 | -13.58 | -110.56 | -182.02 | -220.68 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 176 | 167 | 152 | 138 | 109 | 98 |
Shares Outstanding (Diluted) | 176 | 167 | 152 | 138 | 109 | 98 |
Shares Change | 7.15% | 9.35% | 10.36% | 26.87% | 10.57% | 8.48% |
EPS (Basic) | -0.18 | -0.12 | -0.09 | -0.80 | -1.67 | -2.24 |
EPS (Diluted) | -0.18 | -0.12 | -0.09 | -0.80 | -1.67 | -2.24 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -20.86 | -27.91 | -24.24 | -60.33 | -148.74 | -206.38 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -0.12 | -0.17 | -0.16 | -0.44 | -1.37 | -2.10 |
Gross Margin | 71.12% | 73.31% | 73.21% | 48.75% | 49.04% | 46.70% |
Operating Margin | -6.94% | -1.64% | -7.99% | -87.07% | -162.21% | -252.27% |
Profit Margin | -6.94% | -13.04% | -9.41% | -87.02% | -169.05% | -255.58% |
FCF Margin | -13.84% | -18.02% | -16.80% | -47.49% | -138.14% | -239.01% |
EBITDA | -8.17 | -0.22 | -9.04 | -107.72 | -171.77 | -214.81 |
EBITDA Margin | -5.42% | -0.14% | -6.26% | -84.79% | -159.53% | -248.78% |
EBIT | -10.46 | -2.54 | -11.53 | -110.62 | -174.66 | -217.83 |
EBIT Margin | -6.94% | -1.64% | -7.99% | -87.07% | -162.21% | -252.27% |